As with any medication, there are potential side effects, including nausea, vomiting, diarrhea, and constipation, and it may not be suitable for everyone
Bioglutide is a first-in-class oral quadruple receptor agonist (GLP-1/GIP/glucagon/IGF-1) with ambitious Phase 2 data but very limited clinical validation
The FDA warns that these products are of unknown quality and may be harmful
This may further help limit excessive glucose production by the liver
Quick Answer: GLP-1 medications typically cause modest blood pressure reductions of 2-6 mmHg, but some patients may experience symptomatic low blood pressure, particularly when combined with antihypertensive medications, significant weight loss, or dehydration from gastrointestinal side effects
Microdosing GLP-1 for Hashimoto's: Evidence, Risks and NHS Guidance Microdosing GLP-1 for Hashimoto's has emerged as a topic of interest amongst patients seeking metabolic support for autoimmune thyroid disease
